Updated trial data shows Pfizer Covid-19 vaccine 91% effective, protects against South African variant: Makers

NEW YORK (REUTERS) - Pfizer and BioNTech said on Thursday (April 1) their Covid-19 vaccine is around 91 per cent effective at preventing the disease, citing updated trial data that included participants inoculated for up to six months.
The shot was also 100 per cent effective in preventing illness among trial participants in South Africa, where a new variant called B1351 is dominant, although the number of those participants was relatively small at 800.
While the new overall efficacy rate of 91.3 per cent is lower than the 95 per cent originally reported in November for its 44,000-person trial, a number of variants have become more prevalent around the world since then.

Related Keywords

South Africa ,United States ,United Kingdom ,Brazil ,Britain ,South African ,Albert Bourla ,Ugur Sahin ,Danny Altmann ,Pfizer ,Britain Imperial College London ,Drug Administration ,Disease Control ,Imperial College London ,Vaccines ,Corona Virus ,Covid 19 ,ஒன்றுபட்டது மாநிலங்களில் ,ஒன்றுபட்டது கிஂக்டம் ,பிரேசில் ,பிரிட்டன் ,டேனி அல்டமான் ,ஃபைசர் ,பிரிட்டன் ஏகாதிபத்தியம் கல்லூரி லண்டன் ,நோய் கட்டுப்பாடு ,ஏகாதிபத்தியம் கல்லூரி லண்டன் ,தடுப்பு மருந்துகள் ,கொரோனா வைரஸ் ,